Controversial, Ill-Fated Obesity Drug Trial Published In JAMA
The final– but now largely useless– results of the cardiovascular safety trial of the obesity drug Contrave have now been published in JAMA, one year after the trial’s dramatic and scandalous crash and burn. By way of background: Contrave is a combination of naltrexone and bupropion marketed as a weight loss drug by Orexigen and...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Contrave CVOT LIGHT Study Nissen obesity Orexigen patent application Source Type: blogs
More News: Bupropion | Burns | Cardiology | Cardiovascular | Eating Disorders & Weight Management | Epidemiology | Heart | Medical Ethics | Obesity | PET Scan | Study | Weight Loss | Wellbutrin